SRR1516050
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR8943010 | — | — | 0.944 |
| 2 | MDT-AP-1160 | Med | Medulloblastoma | 0.943 |
| 3 | SRR1516040 | — | — | 0.940 |
| 4 | TCGA-E7-A3Y1-01A-11R-A22U-07 | — | — | 0.936 |
| 5 | SRR1797231 | — | cohortSC | 0.934 |
| 6 | SRR12202440 | — | — | 0.932 |
| 7 | SRR23303736 | — | — | 0.929 |
| 8 | SRR650197 | — | — | 0.926 |
| 9 | SRR11296796 | — | — | 0.922 |
| 10 | SRR1334717 | GTEX | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.160 | Remibrutinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.040 | Inavolisib | — uncovered |